NanoViricides, Inc. Finds FluCide(TM)-I Superior To Oseltamivir In Preliminary Animal Studies, Presents Data At The 7th Annual Targeted Nano-delivery Conference

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides (Pink Sheets: NNVC) President and Chairman, Dr. Anil Diwan, presented preliminary data on animal studies that compare nanoviricides drug candidates with oseltamivir (Tamiflu(R) Roche) on Friday, Oct. 13th at the 7th Annual Targeted Nano-delivery Conference in Baltimore, MD.
MORE ON THIS TOPIC